List of Excipients in Branded Drug FLULAVAL

FLULAVAL Excipient Strategy, Formulation Patents, Regulatory Status, and Commercial Opportunities

Last updated: September 5, 2026

Flulaval is a split-virion, inactivated influenza vaccine marketed by GSK. Its excipient strategy is conservative: an isotonic phosphate-buffered aqueous system, polysorbate 80 for formulation stability, and thimerosal only in multidose presentations. The largest commercial opportunities are not new active ingredients. They are preservative-free multidose systems, improved container-closure performance, reduced residual-process impurities, cold-chain resilience, and excipient platforms that can be transferred across seasonal influenza vaccines.

Flulaval’s excipients are unlikely to create a standalone high-value patent barrier. Competitive protection is more likely to arise from manufacturing controls, strain-specific processes, stability data, device configuration, and regulatory execution.

What excipients are used in Flulaval?

Flulaval contains inactivated influenza virus antigens produced in embryonated chicken eggs. The U.S. formulation uses a buffered isotonic solution with polysorbate 80. Multidose vials contain thimerosal as a preservative. The precise excipient profile depends on the presentation and applicable seasonal label.

Component	Function in Flulaval	Commercial relevance
Sodium chloride	Isotonicity control	Low differentiation; standard vaccine excipient
Potassium chloride	Ionic balance and isotonicity	Low differentiation
Phosphate salts	pH buffering	Important for antigen stability and compatibility
Magnesium chloride	Ionic environment and process formulation	Low standalone value
Calcium chloride	Ionic balance	Low standalone value
Polysorbate 80	Surfactant; limits adsorption and aggregation	Potential stability and container-closure focus
Thimerosal	Preservative in multidose vials	Commercial differentiation point because many purchasers prefer preservative-free products
Residual formaldehyde	Process residual, not an intentional formulation excipient	Requires specification and analytical control
Residual ovalbumin	Egg-derived process residual	Relevant to labeling, safety, and manufacturing control
Residual antibiotics or process chemicals	Manufacturing residuals, where applicable	Regulatory and quality-control issue

The Flulaval prescribing information describes a 0.5 mL dose containing 15 micrograms of hemagglutinin from each influenza strain in the quadrivalent product. The product is supplied in single-dose syringes, single-dose vials, and multidose vials, with presentation-specific preservative status stated in the labeling.[1]

How does the Flulaval formulation work?

Flulaval is not an adjuvanted influenza vaccine. Its formulation uses conventional buffering, salts, and surfactant technology rather than an immune-stimulating adjuvant system.

The excipient system has four main technical objectives:

1. Maintain a near-physiologic ionic environment.
2. Control pH during storage.
3. Reduce antigen adsorption to glass, elastomer, and delivery-device surfaces.
4. Preserve product quality through refrigerated storage and routine handling.

Polysorbate 80 is the most commercially relevant non-buffer excipient. In vaccine formulations, it can reduce interfacial stress and surface adsorption. Its use also creates development requirements because oxidation, hydrolysis, peroxide formation, and interaction with container materials can affect product quality.

The buffer system is technically ordinary but operationally important. Small changes in pH, ionic strength, or excipient concentration can affect hemagglutinin integrity, particle size, aggregation, potency assays, and container compatibility. A replacement formulation would therefore require comparative stability and potency evidence rather than a simple excipient substitution.

What formulation patents protect Flulaval?

Public product information identifies the formulation ingredients but does not establish a current, enforceable, product-specific patent estate covering the commercial Flulaval dose form. The core excipients are well-known pharmaceutical and vaccine materials. Sodium chloride, phosphate buffers, calcium and magnesium salts, and polysorbate 80 generally provide limited composition-of-matter patent leverage.

Potentially protectable areas include:

Potential protection area	Patent strength for a Flulaval-like product	Business implication
Basic buffered saline formulation	Low	Difficult to distinguish from prior art
Use of polysorbate 80 in an influenza vaccine	Low to moderate	Requires narrow stability or concentration claims
Reduced- or no-polysorbate formulations	Moderate	Could protect improved oxidation or compatibility performance
Preservative-free multidose presentations	Moderate	Value depends on container and microbial-control solution
Specific prefilled syringe or vial configuration	Moderate	Device and container patents may apply
Improved antigen stability during shipping	Moderate to high	Stronger if linked to measurable shelf-life or excursion performance
Residual impurity reduction	Moderate	Manufacturing-process claims may be more defensible
Strain-specific seasonal composition	Low to moderate	Seasonal replacement reduces long-term exclusivity value
Manufacturing and purification process	Moderate to high	Process know-how can be more important than excipient claims

A patent strategy centered solely on the known Flulaval excipients would be weak. A stronger strategy would claim a defined formulation together with a measurable technical result, such as improved hemagglutinin recovery, lower aggregation, longer stability after temperature excursion, reduced polysorbate degradation, or improved compatibility with a specific syringe or vial system.

Is Flulaval listed in the Orange Book?

Flulaval is not an Orange Book product in the conventional small-molecule sense. FDA’s Orange Book primarily addresses approved drug products submitted through the drug approval pathways, including patents and regulatory exclusivity associated with those products. Flulaval is a biologic vaccine licensed under the Public Health Service Act through a biologics license application.

Biologic reference products are generally evaluated through the Purple Book and the applicable FDA biologics framework rather than through Orange Book listing and certification procedures.[2] A competitor therefore does not normally challenge Flulaval through an ANDA Paragraph IV filing.

Does Flulaval face Paragraph IV challenges?

No conventional Paragraph IV pathway applies to Flulaval. Paragraph IV litigation is associated with abbreviated new drug applications for small-molecule drugs. Seasonal influenza vaccines are regulated as biologics and require a biologics license or other applicable CBER pathway.

A competitor could challenge relevant patents through ordinary patent litigation, declaratory judgment, licensing negotiations, or a separate biologics development program. The procedural and evidentiary framework differs from generic drug litigation.

When does Flulaval lose exclusivity?

Flulaval does not have a single practical loss-of-exclusivity date comparable to a tablet drug with one active patent and one Orange Book listing.

Its commercial exclusivity is influenced by:

• The duration and scope of any enforceable formulation, process, device, or use patents.
• The BLA regulatory framework.
• Annual strain selection and seasonal manufacturing.
• Manufacturing capacity and supply contracts.
• FDA review of competing influenza vaccines.
• Institutional purchasing and public-sector tenders.
• The ability of competitors to establish comparable immunogenicity, safety, and lot-release controls.

Seasonal influenza vaccines also have a short commercial cycle. A product may have regulatory approval across multiple seasons, but each season requires updated strain composition and manufacturing activity. This limits the value of long-dated formulation patents unless they apply broadly across updated strains and presentations.

What commercial opportunities exist for Flulaval excipients?

Preservative-free multidose presentations

The clearest opportunity is a multidose product that avoids thimerosal while maintaining microbial safety after repeated vial access. This would require a validated container-closure and antimicrobial-control strategy. Potential technologies include:

• Improved septum and stopper systems.
• Low-permeability vial components.
• Integrated administration devices.
• Restricted-access or unit-dose delivery formats.
• Manufacturing and handling controls that reduce contamination risk.

A preservative-free multidose configuration could appeal to pediatric, hospital, occupational-health, and public-sector purchasers. The value would depend on total delivered cost, not only excipient composition.

Polysorbate alternatives and stabilization systems

A second opportunity is a lower-polysorbate or polysorbate-free formulation. Development targets could include nonionic surfactants, amino-acid systems, sugar-based stabilizers, or combinations designed to limit aggregation and surface loss.

The technical barrier is proof that the replacement system maintains:

• Hemagglutinin potency.
• Particle-size distribution.
• Low aggregation.
• Acceptable appearance.
• Stability through the labeled shelf life.
• Compatibility with glass, elastomer, and syringe materials.
• Comparable clinical performance.

A novel stabilizer may have stronger patent potential than the standard Flulaval buffer, particularly if it produces a defined improvement under accelerated or excursion conditions.

Cold-chain and temperature-excursion protection

Flulaval is refrigerated. A formulation or container system that tolerates short temperature excursions could reduce wastage in pharmacies, clinics, mobile vaccination programs, and international distribution.

Commercially attractive claims could cover:

• Stability after repeated temperature excursions.
• Reduced potency loss during short-term exposure above refrigerated conditions.
• Improved freeze-thaw resistance.
• Compatibility with smaller insulated shipping systems.
• Longer allowable in-use periods after vial puncture.

The regulatory value of this work would depend on validated stability data and a label-supported storage change.

Low-extractables and low-leachables systems

A vaccine supplier can differentiate through vial, stopper, syringe, and plunger systems that reduce extractables and leachables. This area is particularly relevant where formulations contain surfactants, because surfactants can alter interactions with packaging materials.

Potential IP may cover:

• Elastomer composition.
• Coatings or barrier layers.
• Silicone-reduced syringes.
• Container-closure combinations.
• Storage conditions that limit leachable formation.

This opportunity is broader than Flulaval because the same packaging platform could be used for other injectable biologics.

Residual impurity reduction

Egg-based influenza vaccine manufacturing creates opportunities to reduce or better control residual ovalbumin, formaldehyde, antibiotics, and other process-related substances. These opportunities are primarily process and analytical rather than conventional excipient opportunities.

Commercial value can arise from:

• Improved purification.
• Lower residual impurity specifications.
• More sensitive release assays.
• Process changes that reduce lot variability.
• Manufacturing platforms that support broader patient labeling.

The strongest claims would connect the process to a measurable impurity reduction without reducing antigen recovery or increasing production cost.

How strong is the patent estate for Flulaval?

The likely strength profile is mixed.

IP category	Relative strength	Reason
Standard excipient composition	Weak	Ingredients are established and widely used
Product-specific concentration ranges	Weak to moderate	Vulnerable to prior art unless tied to unexpected results
Polysorbate degradation control	Moderate	Technical data can support narrower claims
Container-closure system	Moderate	Device and packaging claims can create practical barriers
Egg-based manufacturing process	Moderate to strong	Process complexity and know-how matter
Seasonal strain composition	Limited	Composition changes across seasons
Cold-chain stability	Moderate to strong	Stronger when supported by validated shelf-life data
Preservative-free multidose system	Moderate	Requires integrated formulation, packaging, and microbiology evidence

Trade secrets may matter more than patents in several areas. These include antigen purification parameters, inactivation conditions, filtration settings, hold times, mixing order, filling controls, and stability-indicating assays. Such information can delay competition even when the public formulation is simple.

What generic entry risks exist for Flulaval?

The risk is not conventional generic substitution. A competitor must establish an approved vaccine product, manufacturing capability, strain-update process, quality system, and commercial supply network.

The principal entry scenarios are:

1. A competing egg-based inactivated influenza vaccine with similar presentations.
2. A cell-based or recombinant influenza vaccine competing on manufacturing or supply-chain attributes.
3. A preservative-free product targeting institutional purchasers.
4. A prefilled or device-integrated product targeting administration efficiency.
5. A lower-cost manufacturer competing for public-sector volume.
6. A product with improved stability or reduced cold-chain requirements.

The main commercial barriers are annual production timing, capacity reservations, demand forecasting, lot-release testing, and procurement qualification. Patent litigation may be less important than manufacturing readiness and supply reliability.

How does Flulaval compare with competing influenza vaccines?

Product type	Formulation opportunity	Main competitive advantage
Flulaval, egg-based inactivated vaccine	Conventional buffer and surfactant optimization	Established supply and broad seasonal use
Fluzone, egg-based inactivated vaccine	Presentation and dose-format differentiation	Sanofi scale and portfolio breadth
Flucelvax, cell-based vaccine	Cell-substrate manufacturing and reduced egg dependence	Alternative production platform
Flublok, recombinant vaccine	Recombinant antigen and manufacturing process	Egg-free production and higher-dose positioning in some products
Fluad, adjuvanted vaccine	Adjuvant system and older-adult targeting	Enhanced immune response positioning
Nasal influenza vaccines	Intranasal delivery and mucosal response	Administration convenience and needle avoidance

Flulaval’s strongest excipient-related positioning is cost-efficient, conventional injectable delivery. Its weaker position is differentiated stability or immune enhancement, where competitors may rely on cell-based, recombinant, adjuvanted, or intranasal technologies.

What is the FDA regulatory status of Flulaval?

Flulaval is an FDA-authorized influenza vaccine product marketed under GSK’s biologics license. Seasonal influenza vaccines are updated as recommended strains change. FDA reviews the seasonal composition and manufacturing data within the biologics regulatory framework.[1,3]

Any new excipient strategy would require a regulatory assessment based on the magnitude of the formulation change. A minor change within an established formulation platform may rely on comparability and stability data. A new preservative system, new surfactant, new container, or materially different dose form could require expanded nonclinical, quality, and clinical support.

The highest-value development path is usually an excipient change that improves a labeled product attribute without changing the antigen dose or intended immune response.

What licensing opportunities exist for Flulaval excipient technology?

Licensing opportunities are strongest for platform technologies that apply beyond Flulaval. Attractive packages could include:

• Preservative-free multidose delivery.
• Polysorbate replacement.
• Low-extractables container systems.
• Temperature-excursion stabilization.
• Improved egg-derived antigen purification.
• Integrated syringe and vaccine-container technologies.
• Analytical methods for surfactant degradation and aggregation.

A licensor should seek claims that cover the formulation, manufacturing method, container system, and use across multiple influenza strains. A single-season or single-brand claim has limited value because vaccine composition changes regularly.

Key Takeaways

• Flulaval uses a conventional buffered isotonic formulation with polysorbate 80.
• Thimerosal is associated with multidose presentations, making preservative-free delivery a practical commercial opportunity.
• The standard excipients are unlikely to support a strong standalone composition patent.
• Better patent prospects exist in stability, packaging, temperature-excursion control, residual impurity reduction, and manufacturing processes.
• Flulaval is regulated as a biologic vaccine, not as an Orange Book small-molecule drug.
• Paragraph IV generic litigation is not the normal competitive pathway.
• Biosimilar-style competition is less relevant than independent seasonal vaccine development and biologics licensing.
• Manufacturing capacity, seasonal timing, public procurement, and supply reliability may create stronger barriers than excipient patents.
• Excipient technologies with value across multiple influenza vaccines have greater licensing potential than Flulaval-specific claims.

FAQs

Can polysorbate 80 be removed from Flulaval?

Potentially, but removal would require comparative stability, potency, aggregation, container-compatibility, and regulatory data. A replacement is commercially valuable only if it provides a measurable benefit.

Does thimerosal protect Flulaval from microbial contamination?

Yes. In applicable multidose presentations, thimerosal functions as a preservative. Single-dose presentations generally avoid the need for a multidose preservative system.

Can an excipient company obtain a patent on a Flulaval-compatible formulation?

Yes, but a patent would need meaningful novelty and inventive step. Claims directed only to common buffers, salts, or polysorbate 80 would face substantial prior-art risk.

Is Flulaval exposed to biosimilar competition?

Not in the same way as a therapeutic monoclonal antibody. Seasonal influenza vaccines are more likely to face independently developed competing vaccines evaluated through biologics regulatory pathways.

Which excipient technology has the highest commercial potential?

Preservative-free multidose delivery and temperature-excursion stability have the clearest commercial rationale. Both can reduce operational costs and support broader use across vaccine products.

References

1. GSK. (2024). Flulaval Quadrivalent influenza vaccine prescribing information. U.S. Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/vaccines/flulaval
2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
3. U.S. Food and Drug Administration. (2024). Seasonal influenza vaccine supply and strain selection information. https://www.fda.gov/vaccines-blood-biologics/influenza-vaccine-composition-and-selection
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
5. U.S. Pharmacopeia. (2024). General chapter <1663>: Assessment of extractables associated with pharmaceutical packaging and delivery systems. United States Pharmacopeial Convention.